(Arg)9 TFA

Research use only, not for human use.

(Arg)9 TFA (Nona-L-arginine TFA), a cell-penetrating peptide, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective.

(Arg)9 TFA (Nona-L-arginine TFA), a cell-penetrating peptide, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM).(Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume.

(Arg)9 (Nona-L-arginine; 5-10 μM) TFA provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 TFA is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 TFA also shows neuroprotection following in vitro ischemia (IC50=6 μM).

(Arg)9 (Nona-L-arginine; 1?μM/kg (600? μL); i.v.; once, for 30min; male Sprague–Dawley ratspermanent middle cerebral artery stroke model) TFA shows neuroprotective effects and reduces infarct volume. Animal Model:Male Sprague–Dawley rats (270 to 320?g) permanent middle cerebral artery stroke model Dosage:1 μM/kg (600? μL) Administration:Intravenous injection; once, over 5 minutes Result:Reduced significantiy 20% in infarct volume.

Nona-L-arginine (TFA),Peptide R9 (TFA)

Others

Other Targets

neuroprotection

Others

Saphenous Vein Graft Disease

2283335-13-5

1537.71

C56H111N36F3O12

>98% (HPLC)

H2O

OC(=O)C(F)(F)F.N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years